Preclinical leadership Epistem Ltd. offers a broad suite of preclinical services including oncology, inflammatory, dermatology, autoimmune and GI disease models, plus GI tox expertise and novel stem cell assays. This positions the company to target pharma and biotech partners seeking end-to-end preclinical support and specialized toxicity testing.

Biomarker excellence With GCLP compliant genetic testing, histology, FACS, and protein biomarker detection, Epistem can partner with clients accelerating biomarker-driven drug development, enabling companion diagnostics opportunities and patient stratification strategies.

Genomics edge Proprietary low input techniques enabling gene expression and DNA genotyping from minimal material (down to single cells) and innovative uses of plucked hair and laser capture microdissection open avenues for niche biomarker programs and early-stage exploratory studies.

Strategic partnerships Strong client base across 200+ pharma/biotech entities with high repeat business indicates reliability and satisfaction. Target expansion through CRO collaborations, tiered service packages, and co-development pilots could deepen wallet share.

Growth signals Recent leadership hires in business development and ongoing presence at major conferences (AACR, ESMO, Biomarkers) suggest a push to scale sales, broaden market reach in translational research, and win larger multi-year contracts.